

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

IMMUNOMEDICS INC  
Form 8-K  
February 11, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

-----  
Date of Report (Date of earliest event reported):  
February 9, 2004

IMMUNOMEDICS, INC.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-12104 (Commission File Number)	61-1009366 (IRS Employer Identification No.)
--	--	--

300 American Road  
Morris Plains, NJ 07950  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (973) 605-8200

Not applicable  
(Former name or former address, if changed since last report)

-----  
Item 7. Financial Statements and Exhibits.

(c)

Exhibits.

99.1

Earnings release dated February 9, 2004 for the three and six months ended December 31, 2003.

Item 9. Regulation FD Disclosure.

On February 9, 2004, Immunomedics, Inc. announced its financial results for the three and six months ended December 31, 2003. The earnings release for the interim periods is attached hereto as an exhibit to this current report on Form 8-K and is being furnished pursuant to Item 12 of Form 8-K.

In accordance with the procedural guidance in SEC Release No. 33-8216, the information in this Form 8-K and the Exhibit attached to this Form 8-K are being furnished under "Item 9. Regulation FD Disclosure" in satisfaction of the

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

requirements of "Item 12. Disclosure of Results of Operations and Financial Condition." The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

2

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.  
(Registrant)

Date: February 11, 2004

By: /s/ CYNTHIA L. SULLIVAN

-----  
Cynthia L. Sullivan  
President and Chief Executive Officer

3

---

EXHIBIT INDEX

Exhibit Number	Description
-----	-----
99.1	Earnings release dated February 9, 2004 for the three and six months ended December 31, 2003.

---